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AbstrACt
background National Health Service policy suggests 
that increasing usage of electronic personal health 
records (PHR) by patients will result in cost savings and 
improved public health. Medication adherence means that 
patients take their prescribed medication as agreed with 
their doctors. Some of the claimed benefits of PHRs are 
decreasing healthcare costs and improving medication 
adherence and patient outcomes.
Methods This is a mixed methods convergent study, 
primarily qualitative. The qualitative and quantitative data 
collection and analysis will occur in parallel, and then be 
synthesised. We are interviewing and surveying adults 
with long- term conditions to identify what are the most 
important and useful features of their current PHR. The 
data collection comprises patient demographics, the 
Medication Adherence Questionnaire, the personality scale 
Big Five Inventory-2 Extra- Short Form and the WHO Quality 
of Life- BREF scale. Qualitative data will be analysed using 
the Framework method.
Ethics We have received a favourable ethical opinion from 
the Health Research Authority/Research Ethics Committee.
bACkground
The WHO reported that medication adher-
ence in patients with long- term conditions 
averages to 50% in developed countries.1 
Based on the results of a 2017 US survey, 
roughly 40% of patients who are chron-
ically ill were interested in using technology 
to assist them with medication, diagnosis, 
test results and managing their condition in 
their home environment.2 National Health 
Service (NHS) England policies published 
over the past decade such as Personalised 
Health and Care 2020 (PHC2020)3 and the 
Five Year Forward View4 specify that the NHS 
needs to use information and communica-
tion technologies (ICT) to reduce healthcare 
costs and improve healthcare outcomes. The 
most recent NHS policy document, The NHS 
Long Term Plan,5 focuses on ‘personalised 
healthcare’ to improve quality of life and 
public health and aspires that over the next 
5 years with the introduction of further ICT, 
outpatient visits will drop by one- third. The 
aim is that people with long- term conditions 
such as diabetes, respiratory or renal prob-
lems will have further access to technology 
designed to help them manage their condi-
tion, for example, continuous glucose moni-
toring for all pregnant patients with type 1 
diabetes.
Recent literature suggests that there is 
limited evidence that the use of health appli-
cations can improve patient adherence to 
prescribed medication, and the quality of the 
evidence is often questionable.6–8 The impact 
of ICT on cost, quality and safety of health-
care remains questionable, based on the 
conflicting evidence of more ‘optimistic’9–11 
versus more cautious studies.6
Medication adherence is ‘the extent to which a 
person’s behaviour—taking medication, following 
a diet, and/or executing lifestyle changes, corre-
sponds with agreed recommendations from a health-
care provider’12 and is considered a well- known 
challenge in healthcare,13 acknowledged by 
PHC2020.3 The ABC taxonomy14 is selected 
as the conceptual framework for medication 
adherence in this study, since it is well cited 
and it is considered more comprehensive 
than the WHO Five interacting dimensions 
that affect adherence,12 which will still inform 
this study as a secondary source.
It is widely suggested in the literature that 
medication adherence should be measured 
in conjunction with quality of life in order to 
define whether a patient’s health is better.15 16 
Health- related quality of life (HRQoL) is the 
‘subjective assessment of the impact of disease 
and treatment across the physical, psychological, 
social and somatic domains of functioning and 
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well- being’.13 Literature also suggests that patient person-
ality traits often affect medication adherence.17 18 The 
Five- Factor Model is an established taxonomy of person-
ality traits.19 According to it, personality can be described 
in terms of five basic personality trait dimensions: agree-
ableness, conscientiousness, extraversion, neuroticism 
and openness to experience.20 21
The NHS standards for commissioning personal health 
records (PHR)22 provide guidance on good practice for 
the development of PHRs in England, but they do not 
provide enough evidence on how the PHR standards 
impact public health, nor on what design features should 
a PHR include nor evidence on how these features 
impact health outcomes. PHRs are ‘online systems that 
include collections of patients’ healthcare and medical data, 
which utilise health informatics standards to enable patients to 
share, organize and manage these data according to their own 
views’.7 Some of the many claimed benefits of PHRs are 
the ability of PHR to improve patient outcomes, decrease 
healthcare costs, allow patients the ability to self- manage 
their health, empower patients and improve medication 
adherence.23–25
Aim and objectives
The aim of this study is to determine how best comput-
erised PHR features should be designed to help patients 
get the full benefit of their prescribed medication. It 
could be hypothesised that health and information tech-
nology literacy may be important factors in identifying 
these essential PHR design features. Health literacy is ‘the 
degree to which individuals have the capacity to obtain, process, 
and understand basic health information and services needed to 
make appropriate health decisions’.26 The Health Education 
England defines digital literacy as ‘the capabilities that fit 
someone for living, learning, working, participating and 
thriving in a digital society’.27
Primary objective
Identify the essential design features of PHRs to 
improve medication adherence in adults with long- term 
conditions.
Secondary objectives
 ► Identify how patient and disease- specific factors 
mediate the impact of PHRs.
 – Patient specific: personality traits and 
sociodemographics.
 – Disease specific: progression, severity, intervention 
type, polypharmacy.
 ► Develop a theoretical model that describes the inter-
action between the PHR design features and the 
patient and disease- specific factors, to help determine 
what works for whom in what circumstances.
MEthods
In the absence of a comprehensive checklist for our 
mixed methods study design, we have adopted the 
Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) statement28 given that our 
study is observational. The STROBE statement covers 
cohort, case–control and cross- sectional studies and we 
will follow the relevant statement’s sections about the 
cohort (for our qualitative data) and cross- sectional (for 
our quantitative data) studies.
study design
This study will follow the mixed methods research meth-
odology, based on a pragmatist perspective, which is 
considered appropriate in the literature for medical infor-
matics.29 30 The convergent mixed methods design31 will 
be used. The convergent design (or parallel or concur-
rent32 33) is parallel and both qualitative and quantitative 
data are gathered at the same time, are analysed sepa-
rately and then synthesised. The purpose of this design 
is to gather complementary data for the topic and aims 
to mitigate the pitfalls of solely quantitative or qualitative 
approaches, by illustrating quantitative and qualitative 
results together and examining relationships between 
variables. The results can then be merged and compared 
to answer the study’s aims and objectives.31 34 In this study, 
the qualitative data have been identified as dominant,34 
as the area is largely under- researched and complex. The 
quantitative data will supplement and indicate the extent 
with which findings from the qualitative work are present. 
Figure 1 illustrates the different stages of the research 
and a more detailed explanation follows.
This study’s evaluation is based on the Medical 
Research Council guidance on developing and evalu-
ating complex interventions35 that emphasises the impor-
tance of assessing the effectiveness and the outcomes of 
complex interventions contextually in interventions that 
are currently implemented and cannot be reversed.
This study will use the realist evaluation framework36 
as its overarching theoretical approach to identify the 
optimal configurations of context, mechanism and 
outcomes in the use of PHRs for medicine optimisation. 
A realist evaluation includes a contextual evaluation (in 
what circumstances),37 a process evaluation (what works 
for whom)38 and outcomes evaluation (how). This holistic 
evaluation approach makes realist evaluation framework 
an ideal candidate to deal with the uncertainty and the 
complexity of interventions in medical informatics.39 40
The evaluation36 will begin with the construction of 
an initial programme theory (table 1), informed by the 
literature review,7 8 which identifies the outcomes that are 
derived from the intervention and what mechanisms are 
in place to generate these outcomes as well as what context 
will affect them. The context–mechanism–outcome 
(CMO) configuration will be used as analytical approach, 
to identify mechanisms and contextual factors that are 
associated with the variation in outcomes.36 The study will 
iteratively revise the programme theory complying with 
the realist evaluation principles.
sampling and recruitment
Based on the study’s intention to directly relate the data 
sets, as well as to avoid influencing our ability to converge 
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Figure 1 Study design. BFI-2- XS, Big Five Inventory-2 Extra- Short Form; MAQ, Medication Adherence Questionnaire; 
WHOQOL- BREF, WHO Quality of Life- BREF.
the results, we will use the same individuals to participate 
in both the quantitative and the qualitative strands of the 
study.34 The primary data of this study are qualitative; thus 
the sampling strategy is based on the qualitative compo-
nent of the study, which will be merged with the quan-
titative data strand. A purposive convenient sample34 of 
participants will be recruited from volunteers through a 
variety of methods. The ‘gold standard’ for a purposive 
sample is to achieve saturation, which is impossible to 
predict. Therefore, based on the aims and objectives of 
this study and the type of sampling scheme selected, a 
typical recommendation is medium sample size, roughly 
30–40 participants to achieve theoretical saturation.34
Posters will be displayed in general practitioner 
surgeries, pharmacies in Hampshire and University of 
Portsmouth communal areas. Recruitment flyers will be 
electronically distributed by social media and via groups 
and forums of patients who are chronically ill, such as 
Diabetes UK. A project website will be created that will 
also make available the flyer and information sheets. 
Furthermore, more volunteers will be recruited via char-
ities and other universities and colleges in South East 
England.
Participants
An electronic consent form and demographic informa-
tion including their age and gender will be collected prior 
to the interviews and survey. The recruitment will occur 
in two stages. The first stage will not specify a long- term 
condition; rather we will interview anyone who complies 
with the inclusion criteria and consents. When we reach 
15 (40%) of the intended participants, we will select the 
three majority long- term conditions, as was advised by the 
initial patient and public involvement (PPI) focus group. 
The participant recruitment will finish in August 2019.
Inclusion criteria
 ► Participant is willing and able to provide informed 
consent for participation in the study.
 ► Male or female, aged 18 years or above.
 ► Participant has a long- term condition and is treated 
outside hospital.
 ► Participant is able to self- administer his/her 
medication.
 ► Participant is frequently (at least once a week) using a 
PHR to manage in full or partially his/her medication.
 ► Participant is able to communicate freely.
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Table 1 Initial programme theory (acronyms explained and 
further details provided in the Measures section)
Programme theory
The use of PHR can improve medication adherence in adults 
with chronic conditions.
Context—C
What conditions do we need 
for an intervention to trigger 
mechanisms to produce 
particular outcome patterns?
 ► Adults with long- term 
conditions
 ► Patient- specific 
factors (demographic 
characteristics, health and 
digital literacy)
 ► Disease- specific factors 
(comorbidities, duration of 
condition, severity)
 ► Patient personality traits: 
BFI-2- XS
Mechanism—M
What leads an intervention to 
have a particular outcome in a 
specific context?
 ► PHR design features that 
are used
 ► PHR type (tethered or 
stand- alone)
 ► PHR problems
Outcome pattern—O
What effects do the causal 
mechanisms have when 
triggered in a specific 
context?
 ► PHR benefits
 ► Medication adherence: 
MAQ
 ► Health- related quality of 
life: WHOQOL- BREF
 ► PHR design features that 
would be nice to use
 ► Perceived medication 
adherence and health- 
related quality of life
BFI-2- XS, Big Five Inventory-2 Extra- Short Form; MAQ, Medication 
Adherence Questionnaire; PHR, personal health record; WHOQOL- 
BREF, WHO Quality of Life- BREF.
Exclusion criteria
 ► Participants who are pregnant or terminally ill or 
considered vulnerable adults and patients with cancer.
 ► Adults with medically serious problems that are not 
classified as long- term conditions.
 ► Patients require assistance with taking their 
medication.
 ► Patients unable to communicate or unable to self- 
manage their medication.
 ► Inpatients or patients living in care homes.
Measures
This study will gather qualitative and quantitative data from 
the same population during an online/telephone inter-
view, and will collect extra quantitative data via an online 
survey.
Quantitative data
The Medication Adherence Questionnaire (MAQ) scale 
will be used to measure medication adherence, which is a 
free- to- use four- item scale and has sensitivity (81%), speci-
ficity (44%) and Cronbach’s alpha reliability of 0.61.41 The 
MAQ scale was preferred over the more reliable and widely 
used 8- item Morisky Medication Adherence Scale (MMAS-
8)42 43 or the 13- item Self- Efficacy for Appropriate Medica-
tion Use Scale.44 Both instruments were regarded as too 
long by our PPI group, additionally MMAS-8 is a licence 
product and this study is not resourced for this expenditure.
The WHO Quality of Life- BREF (WHOQOL- BREF)45 
scale will be used to measure HRQoL, which is a free 
licence- based valuable scale for measuring quality of life in 
multiple chronic conditions, scoring 0.92 internal consis-
tency reliability and has validity similar to the 36- Item Short 
Form Survey (SF-36) scale.45 The WHOQOL- BREF was 
preferred over other well- cited measures of HRQoL which 
include the SF-36,46 EuroQoL EQ- 5D47 and the WHOQOL-
100,45 purely for brevity following the PPI advice.
The shortest available form of the Big Five Inventory 
(BFI) questionnaire that is used to measure person-
ality traits, namely the Big Five Inventory-2 Extra- Short 
Form (BFI-2- XS), was selected for this study. Although 
the BFI-2- XS has a lower psychometric scope48 than the 
complete BFI questionnaire,49 it appears to be adequate 
for this study based on PPI advice.
The sociodemographic information that we intend to 
gather is age group, gender, education, domestic status 
and employment status. We will also derive the overall 
participant’s digital and health literacy from the inter-
views. There are a number of ways to measure digital and 
health literacy,50 51 however, we have chosen not to use 
further scales, based on the PPI advice regarding potential 
participation fatigue.52 We will simply infer the degree of 
health and digital literacy as high, medium or low, based on 
generic categorisations in the literature.27 51 Health literacy 
will be inferred from the questions 1, 4 and 5, and digital 
literacy from the questions 1 and 5 of the interview (see 
online supplementary file 1), as well as the employment and 
education status of the participant.27 50 The guideline that 
we use to infer the health and digital literacy is provided in 
the online supplementary file 2.
Qualitative data
Qualitative dimensions of the concepts of effectiveness of 
PHR design features with medication adherence will be 
assessed with a semistructured interview (see online supple-
mentary file 1). Questions that infer the medication adher-
ence and quality of life are included in the interview, to 
strengthen our methodological and analytical approach.34
Analysis
The qualitative data analysis will use the Framework 
method,53 which will enable themes to be developed 
inductively (from the interviews) but also incorporating 
themes identified in the literature review.7 The Frame-
work method is systematic, thorough, data driven but also 
flexible and enables visual representation of the data.53 54 
There are step- by- step guides to the application of the 
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Framework method and this study intends to follow the 
guidelines of Gale et al.54
We will use NVivo V.12 for coding. To achieve coding 
inter- rater reliability, a subset of files (25%) will be coded 
by an independent researcher and then the themes will be 
compared and the inter- rater reliability score will be calcu-
lated.54 After coding the 50% of the transcripts, a frame-
work will be developed in an iterative manner, to apply to 
the rest of the transcripts. The framework will include codes 
that are grouped together and are clearly defined. The 
interpretation of the data will occur in conjunction with the 
quantitative strand during data merging.
We will use Microsoft Excel 2016 for descriptive statis-
tics; namely mean, minimum, maximum, SD and coeffi-
cient of variance.
Joint displays will be used in a fashion similar to 
Vaughan Dickson et al,55 so as the quantitative and qual-
itative results will be analysed thematically based on 
the CMO configuration to identify the essential design 
features of PHRs to improve medication adherence in 
adults with long- term conditions, taking into consider-
ation the different personality types, adherence levels and 
quality of life opinions of the participants.
Patient and public involvement
A PPI focus group with eight participants took place 
at the University of Portsmouth in June 2018. This 
group’s suggestions are taken into consideration by the 
research team. The study protocol has been also reviewed 
and approved by this PPI group. PPI will be involved 
throughout this research, in order to minimise bias, 
increase transparency and ensure approval.
Limitations
This study is limited to the design features of a PHR and 
not the overall design. There are no explicit questions 
in the interview guide regarding usability or interface 
design. Another limitation is that the sample size of this 
study is limited to 30–40 participants. The dominant data 
of this study are the qualitative and it is currently accept-
able in broad literature to interview approximately 40 
people.34 56 Due to time constraints a higher number would 
be unrealistic.
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